PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma
PVR/TIGIT and PD-L1/PD-1 axes play essential roles in tumor immune evasion and could be potential targets for combined immunotherapy. We aimed to evaluate the expression status of the above-mentioned immune markers in lung squamous cell carcinoma (LUSC), and investigate their survival impact and rel...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-10-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523322001607 |
| _version_ | 1811342020194598912 |
|---|---|
| author | Zhenlin Yang Yue Peng Jiachen Xu Ping Chen Zhenshan Zhao Qingyuan Cai Lin Li He Tian Guangyu Bai Lei Liu Shugeng Gao Jie He |
| author_facet | Zhenlin Yang Yue Peng Jiachen Xu Ping Chen Zhenshan Zhao Qingyuan Cai Lin Li He Tian Guangyu Bai Lei Liu Shugeng Gao Jie He |
| author_sort | Zhenlin Yang |
| collection | DOAJ |
| description | PVR/TIGIT and PD-L1/PD-1 axes play essential roles in tumor immune evasion and could be potential targets for combined immunotherapy. We aimed to evaluate the expression status of the above-mentioned immune markers in lung squamous cell carcinoma (LUSC), and investigate their survival impact and relevance with the immune microenvironment and clinicopathological features. We retrospectively collected specimens from 190 LUSC patients, who underwent pulmonary surgeries, and we performed immunohistochemistry assays of PVR, TIGIT, PD-L1, PD-1 and CD8. In our cohort, the positive rate of PVR was 85.8%, which was much higher than the positive rate of PD-L1 at 26.8%. A total of 32 (16.8%) patients demonstrated co-expression of PVR/PD-L1. High TIGIT density was correlated with positive PD-L1 expression, high PD-1 density, and high CD8 density (PD-L1, P=0.033; PD-1, P<0.001; CD8, P<0.001), and positive PVR expression was correlated with positive PD-L1 expression (P=0.046). High TIGIT density and high PVR/TIGIT expression were correlated with advanced TNM stage (TIGIT density, P=0.020; PVR/TIGIT expression, P=0.041). Patients with positive PVR expression, high TIGIT density, high PVR/TIGIT expression and PVR/PD-L1 co-expression exhibited a significantly worse prognosis (PVR, P=0.038; TIGIT, P=0.027; PVR/TIGIT, P=0.014; PVR/PD-L1, P=0.018). Multivariate analysis demonstrated that PVR/PD-L1 co-expression (Hazard ratio [HR], 1.756, 95% CI, 1.152-2.676, P=0.009) was an independent prognostic factor in LUSC patients. In conclusion, we demonstrated the expression status of PVR/TIGIT and PD-L1/PD-1 in LUSC. PVR/PD-L1 co-expression was an independent prognostic factor in LUSC patients and may serve as a potential predictive biomarker for dual-targeting immunotherapy. |
| first_indexed | 2024-04-13T19:03:59Z |
| format | Article |
| id | doaj.art-c70eaddbf01247e39215da5d50314def |
| institution | Directory Open Access Journal |
| issn | 1936-5233 |
| language | English |
| last_indexed | 2024-04-13T19:03:59Z |
| publishDate | 2022-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-c70eaddbf01247e39215da5d50314def2022-12-22T02:34:02ZengElsevierTranslational Oncology1936-52332022-10-0124101501PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinomaZhenlin Yang0Yue Peng1Jiachen Xu2Ping Chen3Zhenshan Zhao4Qingyuan Cai5Lin Li6He Tian7Guangyu Bai8Lei Liu9Shugeng Gao10Jie He11Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuannanli, Beijing, ChinaDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuannanli, Beijing, China; Department of Thoracic Surgery, Beijing Chao-Yang Hospital, Capital Medical University, No. 8 Gongtinanlu, Beijing, ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuannanli, Beijing, ChinaDepartment of Oncology, Yancheng First Hospital, Affiliated Hospital of Nanjing University Medical School, The First People's Hospital of Yancheng, No. 166 Yulongxilu, Yancheng, Jiangsu Province, ChinaDepartment of Thoracic Surgery, Kailuan General Hospital, No. 57 Xinhuadongdao, Tangshan, Hebei Province, ChinaSchool of Life Sciences, Peking University, No. 5 Yiheyuanlu, Beijing, ChinaDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuannanli, Beijing, ChinaDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuannanli, Beijing, ChinaDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuannanli, Beijing, ChinaDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuannanli, Beijing, ChinaDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuannanli, Beijing, China; Corresponding authors.Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 17 Panjiayuannanli, Beijing, China; Corresponding authors.PVR/TIGIT and PD-L1/PD-1 axes play essential roles in tumor immune evasion and could be potential targets for combined immunotherapy. We aimed to evaluate the expression status of the above-mentioned immune markers in lung squamous cell carcinoma (LUSC), and investigate their survival impact and relevance with the immune microenvironment and clinicopathological features. We retrospectively collected specimens from 190 LUSC patients, who underwent pulmonary surgeries, and we performed immunohistochemistry assays of PVR, TIGIT, PD-L1, PD-1 and CD8. In our cohort, the positive rate of PVR was 85.8%, which was much higher than the positive rate of PD-L1 at 26.8%. A total of 32 (16.8%) patients demonstrated co-expression of PVR/PD-L1. High TIGIT density was correlated with positive PD-L1 expression, high PD-1 density, and high CD8 density (PD-L1, P=0.033; PD-1, P<0.001; CD8, P<0.001), and positive PVR expression was correlated with positive PD-L1 expression (P=0.046). High TIGIT density and high PVR/TIGIT expression were correlated with advanced TNM stage (TIGIT density, P=0.020; PVR/TIGIT expression, P=0.041). Patients with positive PVR expression, high TIGIT density, high PVR/TIGIT expression and PVR/PD-L1 co-expression exhibited a significantly worse prognosis (PVR, P=0.038; TIGIT, P=0.027; PVR/TIGIT, P=0.014; PVR/PD-L1, P=0.018). Multivariate analysis demonstrated that PVR/PD-L1 co-expression (Hazard ratio [HR], 1.756, 95% CI, 1.152-2.676, P=0.009) was an independent prognostic factor in LUSC patients. In conclusion, we demonstrated the expression status of PVR/TIGIT and PD-L1/PD-1 in LUSC. PVR/PD-L1 co-expression was an independent prognostic factor in LUSC patients and may serve as a potential predictive biomarker for dual-targeting immunotherapy.http://www.sciencedirect.com/science/article/pii/S1936523322001607Lung squamous cell carcinomaPVRPD-L1PrognosisImmunotherapy |
| spellingShingle | Zhenlin Yang Yue Peng Jiachen Xu Ping Chen Zhenshan Zhao Qingyuan Cai Lin Li He Tian Guangyu Bai Lei Liu Shugeng Gao Jie He PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma Translational Oncology Lung squamous cell carcinoma PVR PD-L1 Prognosis Immunotherapy |
| title | PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma |
| title_full | PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma |
| title_fullStr | PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma |
| title_full_unstemmed | PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma |
| title_short | PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma |
| title_sort | pvr tigit and pd l1 pd 1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma |
| topic | Lung squamous cell carcinoma PVR PD-L1 Prognosis Immunotherapy |
| url | http://www.sciencedirect.com/science/article/pii/S1936523322001607 |
| work_keys_str_mv | AT zhenlinyang pvrtigitandpdl1pd1expressionpredictssurvivalandenlightenscombinedimmunotherapyinlungsquamouscellcarcinoma AT yuepeng pvrtigitandpdl1pd1expressionpredictssurvivalandenlightenscombinedimmunotherapyinlungsquamouscellcarcinoma AT jiachenxu pvrtigitandpdl1pd1expressionpredictssurvivalandenlightenscombinedimmunotherapyinlungsquamouscellcarcinoma AT pingchen pvrtigitandpdl1pd1expressionpredictssurvivalandenlightenscombinedimmunotherapyinlungsquamouscellcarcinoma AT zhenshanzhao pvrtigitandpdl1pd1expressionpredictssurvivalandenlightenscombinedimmunotherapyinlungsquamouscellcarcinoma AT qingyuancai pvrtigitandpdl1pd1expressionpredictssurvivalandenlightenscombinedimmunotherapyinlungsquamouscellcarcinoma AT linli pvrtigitandpdl1pd1expressionpredictssurvivalandenlightenscombinedimmunotherapyinlungsquamouscellcarcinoma AT hetian pvrtigitandpdl1pd1expressionpredictssurvivalandenlightenscombinedimmunotherapyinlungsquamouscellcarcinoma AT guangyubai pvrtigitandpdl1pd1expressionpredictssurvivalandenlightenscombinedimmunotherapyinlungsquamouscellcarcinoma AT leiliu pvrtigitandpdl1pd1expressionpredictssurvivalandenlightenscombinedimmunotherapyinlungsquamouscellcarcinoma AT shugenggao pvrtigitandpdl1pd1expressionpredictssurvivalandenlightenscombinedimmunotherapyinlungsquamouscellcarcinoma AT jiehe pvrtigitandpdl1pd1expressionpredictssurvivalandenlightenscombinedimmunotherapyinlungsquamouscellcarcinoma |